Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 11,257 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neonate Clear all

Conditions: DiGeorge Syndrome, Shprintzen Syndrome, Chromosome Abnormalities, Abnormalities, Multiple, Conotruncal Cardiac Defects
Interventions: Not listed
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Congenital Heart Disease
Interventions: RAPID; Device
Lead sponsor: University of Minnesota; Other
Eligibility: Up to 1 Year
Enrollment: 22 participants
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Sickle Cell Disease, Pulmonary Disease, Renal Disease, Heart Disease
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 4 Years to 65 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Baltimore, Maryland + 2 more

Conditions: Analgesic Affect
Interventions: Nitrous Oxide; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 1 Minute to 3 Months
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Atopic Dermatitis
Interventions: Rocatinlimab Prefilled Syringe, Rocatinlimab AI; Combination Product
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 22
States / cities: Bakersfield, California • Long Beach, California • Los Angeles, California + 19 more

Conditions: Cystic Fibrosis
Interventions: N91115; Drug
Lead sponsor: Nivalis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 19
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 15 more

Conditions: Retinitis Pigmentosa
Interventions: BS01; Drug
Lead sponsor: Bionic Sight LLC; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Teaneck, New Jersey

Conditions: Hyperoxaluria, Primary
Interventions: Oxabact OC5 - Oxalobacter formigenes Strain HC-1; Biological
Lead sponsor: OxThera; Industry
Eligibility: 3 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Adenomatous Polyposis Coli
Interventions: Erlotinib, Sulindac, Placebo A, Placebo B; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 69 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Neurofibromatosis 1, Neurofibromatosis 2, Schwannomatosis, NF2-related Schwannomatosis
Interventions: Not listed
Lead sponsor: The Children's Tumor Foundation; Other
Eligibility: Not listed
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2050
U.S. locations: 1
States / cities: New York, New York

Conditions: Bone Marrow Failure Syndrome, Severe Aplastic Anemia, Severe Congenital Neutropenia, Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Schwachman Diamond Syndrome, Primary Immunodeficiency Syndromes, Acquired Immunodeficiency Syndromes, Histiocytic Syndrome, Familial Hemophagocytic Lymphocytosis, Lymphohistiocytosis, Macrophage Activation Syndrome, Langerhans Cell Histiocytosis (LCH), Hemoglobinopathies, Sickle Cell Disease, Sickle Cell-beta-thalassemia
Interventions: CD34 Stem Cell Selection Therapy; Biological
Lead sponsor: Diane George; Other
Eligibility: Up to 40 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Soft Tissue Sarcoma, Lymphoma, Leukemia, Wilms' Tumor, Osteosarcoma
Interventions: Liposomal Vincristine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cystic Fibrosis
Interventions: Spiro PD personal spirometer; Device
Lead sponsor: University of Michigan; Other
Eligibility: 10 Years to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cervical Spine Fusion
Interventions: Anterior Cervical Discectomy & Fusion, Application of ADAM mechanoacoustic skin sensor; Procedure · Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 88 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Behcet Syndrome
Interventions: Tocilizumab; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Cystic Fibrosis, Nontuberculous Mycobacterial Pulmonary Infection
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 1 Month to 99 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Denver, Colorado • Baltimore, Maryland • Austin, Texas + 4 more

Conditions: Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Healthy Participants
Interventions: Treatment A, Treatment B, Treatment C, Treatment D, Acetaminophen; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Primary Immunodeficiency
Interventions: IGSC 20%; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 6 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 12
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • North Palm Beach, Florida + 8 more

Conditions: Long qt Syndrome, Torsade de Pointes
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 4
States / cities: Boston, Massachusetts • West Roxbury, Massachusetts

Conditions: Down Syndrome
Interventions: Treadmill Training, Supramalleolar Orthoses; Behavioral · Device
Lead sponsor: University of Michigan; Other
Eligibility: 6 Months to 36 Months
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Digestive System Diseases, Pancreatic Disease, Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: DCI 1020; Drug
Lead sponsor: Digestive Care, Inc.; Industry
Eligibility: Up to 2 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Huntington's Disease
Interventions: SAGE-718, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 34
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 28 more

Conditions: CF - Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis Liver Disease
Interventions: Fibroscan; Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Polyneuropathies, Wild Type ATTR Amyloidosis, Wild-Type Transthyretin-Related (ATTR)Amyloidosis, Wild-Type Transthyretin Cardiac Amyloidosis, Transthyretin Amyloidosis
Interventions: patisiran; Drug
Lead sponsor: Austin Neuromuscular Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome

RAPID: a Comparison Study of a Novel Ultrasound Device of Automated Congenital Heart Imaging

Cooperative Assessment of Late Effects for SCD Curative Therapies

A Study to Test the Pain-relieving Effect of Laughing Gas in Infants

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis

Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation

BS01 in Patients With Retinitis Pigmentosa

An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria

A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients

The NF Registry Sponsored by the Children's Tumor Foundation

CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation

Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies

Exploring Novel Interventions to Improve Adherence in Children With Cystic Fibrosis

Measuring Dysphagia After ACDF Surgery Through A Novel Wearable Sensor

Tocilizumab for the Treatment of Behcet's Syndrome

Prospective Healthcare-Associated Links in Transmission of Nontuberculous Mycobacteria

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency

A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes

Treadmill Training and Orthotic Use in Infants With Down Syndrome

Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

Relationship Between the Development of Impaired Glucose Tolerance, the Phenotype of CFLD, and the Risk of Liver Fibrosis

Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy